Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

A Phase I Trial of Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious adverse events, and treatment-related toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of overall survival, rate of progression-free survival, health-related quality of life parameters, overall response rate, immune response, and tumor stem cell antigen expression.

Inclusion Criteria:

• Recurrent glioblastoma
• HLA-A1 and HLA-A2 positive
• Complete resection of tumor

Exclusion Criteria:

• Clinically significant pulmonary, cardiac or other systemic disease
• Presence of an acute infection requiring active treatment with antibiotics/antivirals; prophylactic administration is allowed.
• Known human immunodeficiency virus positivity or acquired immunodeficiency syndrome related illness or other serious medical condition.
• Known history of Hepatitis B or Hepatitis C
• Allergy to Dimethyl sulfoxide (DMSO)
• Allergy to gentamicin